The potential role,of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis

被引:58
作者
Plutzky, J [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Vasc Dis Prevent Program, Boston, MA 02115 USA
关键词
C-REACTIVE PROTEIN; GAMMA PPAR-GAMMA; TISSUE FACTOR EXPRESSION; MACROPHAGE-GENE-EXPRESSION; VASCULAR ENDOTHELIAL-CELLS; CORONARY-HEART-DISEASE; SMOOTH-MUSCLE-CELLS; HUMAN T-LYMPHOCYTES; INSULIN-RESISTANCE; PLASMA-CONCENTRATION;
D O I
10.1016/S0002-9149(03)006143-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increasing attention has focused on the role of inflammation in various chronic diseases, including atherosclerosis. Recent compelling data have begun to unite work from various arenas, such as epidemiology and vascular biology, and even clinical trials to provide evidence for inflammation as a mechanism underlying cardiovascular disease. Inflammation has been implicated in the pathogenesis, progression, and complications of both atherosclerosis and diabetes mellitus-2 complex disorders often found intertwined in patients. Although this story continues to evolve, peroxisome proliferator-activated receptors (PPARs) have been implicated; as a molecular pathway involved in both these disease processes. In vitro data, animal work, and some human studies suggest that synthetic PPAR agonists in clinical use, such as thiazolidinediones, may not only regulate metabolic processes but may also limit inflammatory responses, including some involved in atherosclerosis. (C) 2003 by Excerpta Medica, Inc.
引用
收藏
页码:34J / 41J
页数:8
相关论文
共 104 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]  
Auwerx J, 1996, J Atheroscler Thromb, V3, P81
[3]   Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].
Barroso, I ;
Gurnell, M ;
Crowley, VEF ;
Agostini, M ;
Schwabe, JW ;
Soos, MA ;
Maslen, GL ;
Williams, TDM ;
Lewis, H ;
Schafer, AJ ;
Chatterjee, VKK ;
O'Rahilly, S .
NATURE, 1999, 402 (6764) :880-883
[4]   Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells:: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator troglitazone [J].
Benson, S ;
Wu, J ;
Padmanabhan, S ;
Kurtz, TW ;
Pershadsingh, HA .
AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (01) :74-82
[5]   Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice [J].
Berthou, L ;
Duverger, N ;
Emmanuel, F ;
Langouet, S ;
Auwerx, J ;
Guillouzo, A ;
Fruchart, JC ;
Rubin, E ;
Denefle, P ;
Staels, B ;
Branellec, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2408-2416
[7]   Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2 [J].
Bishop-Bailey, D ;
Hla, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17042-17048
[8]   Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? [J].
Cattley, RC ;
DeLuca, J ;
Elcombe, C ;
Fenner-Crisp, P ;
Lake, BG ;
Marsman, DS ;
Pastoor, TA ;
Popp, JA ;
Robinson, DE ;
Schwetz, B ;
Tugwood, J ;
Wahli, W .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1998, 27 (01) :47-60
[9]   PPARγ is a very low-density lipoprotein sensor in macrophages [J].
Chawla, A ;
Lee, CH ;
Barak, Y ;
He, WM ;
Rosenfeld, J ;
Liao, D ;
Han, J ;
Kang, H ;
Evans, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (03) :1268-1273
[10]   PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation [J].
Chawla, A ;
Barak, Y ;
Nagy, L ;
Liao, D ;
Tontonoz, P ;
Evans, RM .
NATURE MEDICINE, 2001, 7 (01) :48-52